Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.

about

A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials.Long-term efficacy and safety of a third-line treatment with eribulin plus trastuzumab in a young breast cancer patient.

P2860

Q30390845-B02883E1-303F-4025-84D1-72F98BA8463A Q39084613-E7B5871E-1714-415A-BFDF-311E662DAC98

P2860

Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.

Item

http://www.wikidata.org/entity/Q47628083

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Effectiveness and safety of er ...... t of metastatic breast cancer.

@en

Effectiveness and safety of er ...... t of metastatic breast cancer.

@nl

type

Item

label

Effectiveness and safety of er ...... t of metastatic breast cancer.

@en

Effectiveness and safety of er ...... t of metastatic breast cancer.

@nl

prefLabel

Effectiveness and safety of er ...... t of metastatic breast cancer.

@en

Effectiveness and safety of er ...... t of metastatic breast cancer.

@nl

P1476

Effectiveness and safety of er ...... nt of metastatic breast cancer

@en

P2093

Catherine M Kelly

http://www.w3.org/2001/XMLSchema#string

Janice Walsh

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Marine-derived anticancer agents in clinical trials.

A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.

Eribulin -- a review of preclinical and clinical studies.

Eribulin mesylate for the treatment of breast cancer.

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials.

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.

P304

643-650

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2012.698608

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Geraldine O'Sullivan Coyne

P577

2012-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22694309

http://www.w3.org/2001/XMLSchema#string

P921

eribulin mesylate

Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.

about

P2860

P2860

Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921